Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: J Control Release. 2022 Jul 14;349:413–424. doi: 10.1016/j.jconrel.2022.07.008

Fig. 6. Localization of PLN-formulated ICLs in tumor margin 48h post-injection.

Fig. 6.

Mice were injected and imaged as described in Fig. 3. A) DiI PLN and DiD liposomes were coinjected in GL261 mice. Difference in the margin (arrows) localization between PLN-formulated DiI and liposomal DiD in GL261 tumor; B) PLN-formulated DiD and PEGylated liposomal doxorubicin (DOX) were coinjected in GL261 mice (top row) and in genetically engineered invasive mouse models (supratentorial high-grade and diffuse midline glioma, middle and bottom rows). Arrows point to the margin. The size bar is the same for all images. The experiment is repeated twice.